Skip to content
Agentic OS
Menu

Intelligence / Healthtech / FDA 510(k) Clearances / Brixton Biosciences

Approvalsdevice cleared21 Aug 2026

Brixton Biosciences

21 Aug 2026: Device cleared · ReneuRx™ (Neural Ice). Recorded in the openFDA device 510(k) data.

View the source record

Decided
21 Aug 2026
Device
ReneuRx™ (Neural Ice)
Specialty
Orthopedic
Country
United States
Location
Cambridge, MA
Clearance type
Direct
510(k) number
DEN250067
Submitted
2025-12-15
What this signal means

A clearance starts commercialisation: distribution, reimbursement, software and sales hires.

  1. 268 added in the 30 days to 9 Nov 2026.
  2. Cardiovascular leads with 122 clearances, then Radiology (107).
Reach them with AOS

Find the decision makers at Brixton Biosciences

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Across AOS Research

Other records for Brixton Biosciences in our registers.

More in Orthopedic

FDA 510(k) Clearances

See all

Source: openFDA device 510(k) data, data to 9 Nov 2026. Devices FDA found substantially equivalent and cleared for the US market. Decision dates as published by FDA. AOS shows what the public record says; it does not verify or endorse the company.